Travere Therapeutics, Inc.
TVTX· Nasdaq
TVTXTravere Therapeutics, Inc.
Filed Feb 21, 2025 · 10-K · 52 days after period end · 0001438533-25-000010
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $74.79M | $45.06M | $29.34M | — |
| Net Income | -$60.26M | -$90.17M | -$65.82M | -$51.57M |
| EPS Diluted | — | -$1.18 | -$1.03 | — |
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2024 · filed Feb 21, 2025 · 52 d after period end
